American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

被引：12

作者：

Munshi, Pashna N. ^{[1
]}

Hamadani, Mehdi ^{[2
,3
]}

Kumar, Ambuj ^{[4
]}

Dreger, Peter ^{[5
]}

Friedberg, Jonathan W. ^{[6
]}

Dreyling, Martin ^{[7
]}

Kahl, Brad ^{[8
]}

Jerkeman, Mats ^{[9
]}

Kharfan-Dabaja, Mohamed A. ^{[10
,11
]}

Locke, Frederick L. ^{[12
]}

Shadman, Mazyar ^{[13
,14
]}

Hill, Brian T. ^{[15
]}

Ahmed, Sairah ^{[16
]}

Herrera, Alex F. ^{[17
]}

Sauter, Craig S. ^{[18
,19
]}

Bachanova, Veronika ^{[20
]}

Ghosh, Nilanjan ^{[21
]}

Lunning, Matthew ^{[22
]}

Kenkre, Vaishalee P. ^{[23
]}

Aljurf, Mahmoud ^{[24
]}

Wang, Michael ^{[25
]}

Maddocks, Kami J. ^{[26
]}

Leonard, John P. ^{[27
]}

Kamdar, Manali ^{[28
]}

Phillips, Tycel ^{[29
]}

Cashen, Amanda F. ^{[30
]}

Inwards, David J. ^{[31
]}

Sureda, Anna ^{[32
]}

Cohen, Jonathon B. ^{[33
]}

Smith, Sonali M. ^{[34
]}

Carlo-Stella, Carmello ^{[35
,36
]}

Savani, Bipin ^{[37
]}

Robinson, Stephen P. ^{[38
]}

Fenske, Timothy S. ^{[39
]}

机构：

[1] MedStar Georgetown Univ Hosp, Dept Blood & Marrow Transplantat, Washington, DC USA

[2] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA

[3] Med Coll Wisconsin, BMT & Cellular Therapy Program, Milwaukee, WI 53226 USA

[4] Univ S Florida, Morsani Coll Med, Dept Internal Med, Off Res, Tampa, FL 33620 USA

[5] Heidelberg Univ, Dept Med, Heidelberg, Germany

[6] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA

[7] LMU Hosp Munich, Dept Med 3, Munich, Germany

[8] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[9] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden

[10] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA

[11] Mayo Clin, Blood & Marrow Transplantat & Cellular Therapies, Jacksonville, FL USA

[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[13] Fred Hutchinson Canc Res Ctr, Blood & Marrow Transplantat Program, 1124 Columbia St, Seattle, WA 98104 USA

[14] Univ Washington, Seattle, WA 98195 USA

[15] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA

[16] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat &, Houston, TX 77030 USA

[17] City Hope Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[18] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[19] Weill Cornell Med Coll, New York, NY USA

[20] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[21] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[22] Univ Nebraska Med Ctr, Divs Hematol & Oncol, Omaha, NE USA

[23] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol & Oncol, Madison, WI USA

[24] King Faisal Specialist Hosp & Res Ctr, Blood & Marrow Transplantat Program, Riyadh, Saudi Arabia

[25] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[26] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

[27] Weill Cornell Med, Dept Med, New York, NY USA

[28] Univ Colorado, Ctr Canc, Div Hematol Hematol Malignancies & Stem Cell Tran, Denver, CO 80262 USA

[29] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[30] Washington Univ, Sch Med, Div Oncol, Sect Stem Cell Transplantat, St Louis, MO 63110 USA

[31] Mayo Clin, Div Hematol, Rochester, MN USA

[32] Univ Barcelona, Catalan Inst Oncol, Inst Invest Biomed Bellvitge IDIBELL, Clin Hematol Dept, Barcelona, Spain

[33] Winship Canc Inst, Atlanta, GA USA

[34] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[35] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[36] IRCCS Humanitas Res Hosp, Milan, Italy

[37] Vanderbilt Univ, Med Ctr, Blood & Marrow Transplantat Program, 221 Kirkland Hall, Nashville, TN 37235 USA

[38] Univ Hosp Bristol NHS Fdn Trust, London, England

[39] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

来源：

TRANSPLANTATION AND CELLULAR THERAPY | 2021年 / 27卷 / 09期

关键词：

Mantle cell lymphoma; Autologous transplantation; Allogeneic transplantation; Cellular therapy; CAR T cell; Consensus; OPEN-LABEL; INITIAL THERAPY; FOLLOW-UP; TRIAL; IBRUTINIB; YOUNGER; TP53; IMMUNOCHEMOTHERAPY; RITUXIMAB; SURVIVAL;

D O I：

10.1016/j.jtct.2021.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL. (C) 2021 Dr. Mehdi Hamadani. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.

引用

页码：720 / 728

页数：9

共 35 条

[1] Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network [J].

Aukema, Sietse M. ;

Hoster, Eva ;

Rosenwald, Andreas ;

Canoni, Danielle ;

Delfau-Larue, Marie-Helene ;

Rymkiewicz, Grzegorz ;

Thorns, Christoph ;

Hartmann, Sylvia ;

Kluin-Nelemans, Hanneke ;

Hermine, Olivier ;

Dreyling, Martin ;

Klapper, Wolfram .

BLOOD, 2018, 131 (04) :417-420

[2]

Berkman N D., 2008, Methods Guide for Effectiveness and Comparative Effectiveness Reviews

[3] Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients [J].

Chhabra, Saurabh ;

Thapa, Bicky ;

Szabo, Aniko ;

Konings, Steve ;

D'Souza, Anita ;

Dhakal, Binod ;

Jerkins, James H. ;

Pasquini, Marcelo C. ;

Johnson, Bryon D. ;

Hari, Parameswaran N. ;

Hamadani, Mehdi .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (11) :2011-2017

[4] Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 [J].

Damon, Lloyd E. ;

Johnson, Jeffrey L. ;

Niedzwiecki, Donna ;

Cheson, Bruce D. ;

Hurd, David D. ;

Bartlett, Nancy L. ;

LaCasce, Ann S. ;

Blum, Kristie A. ;

Byrd, John C. ;

Kelly, Michael ;

Stock, Wendy ;

Linker, Charles A. ;

Canellos, George P. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6101-6108

[5] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[6]

Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx223, 10.1093/annonc/mdx289]

[7] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [J].

Dreyling, Martin ;

Jurczak, Wojciech ;

Jerkeman, Mats ;

Silva, Rodrigo Santucci ;

Rusconi, Chiara ;

Trneny, Marek ;

Offner, Fritz ;

Caballero, Dolores ;

Joao, Cristina ;

Witzens-Harig, Mathias ;

Hess, Georg ;

Bence-Bruckler, Isabelle ;

Cho, Seok-Goo ;

Bothos, John ;

Goldberg, Jenna D. ;

Enny, Christopher ;

Traina, Shana ;

Balasubramanian, Sriram ;

Bandyopadhyay, Nibedita ;

Sun, Steven ;

Vermeulen, Jessica ;

Rizo, Aleksandra ;

Rule, Simon .

LANCET, 2016, 387 (10020) :770-778

[8] TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy [J].

Eskelund, Christian W. ;

Dahl, Christina ;

Hansen, Jakob W. ;

Westman, Maj ;

Kolstad, Arne ;

Pedersen, Lone B. ;

Montano-Almendras, Carmen P. ;

Husby, Simon ;

Freiburghaus, Catja ;

Ek, Sara ;

Pedersen, Anja ;

Niemann, Carsten ;

Raty, Riikka ;

Brown, Peter ;

Geisler, Christian H. ;

Andersen, Mette K. ;

Guldberg, Per ;

Jerkeman, Mats ;

Gronbaek, Kirsten .

BLOOD, 2017, 130 (17) :1903-1910

[9] A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma [J].

Evens, Andrew M. ;

Winter, Jane N. ;

Hou, Nanjiang ;

Nelson, Beverly P. ;

Rademaker, Alfred ;

Patton, David ;

Singhal, Seema ;

Frankfurt, Olga ;

Tallman, Martin S. ;

Rosen, Steven T. ;

Mehta, Jayesh ;

Gordon, Leo I. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (04) :385-393

[10] Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality [J].

Fenske, Timothy S. ;

Zhang, Mei-Jie ;

Carreras, Jeanette ;

Ayala, Ernesto ;

Burns, Linda J. ;

Cashen, Amanda ;

Costa, Luciano J. ;

Freytes, Cesar O. ;

Gale, Robert P. ;

Hamadani, Mehdi ;

Holmberg, Leona A. ;

Inwards, David J. ;

Lazarus, Hillard M. ;

Maziarz, Richard T. ;

Munker, Reinhold ;

Perales, Miguel-Angel ;

Rizzieri, David A. ;

Schouten, Harry C. ;

Smith, Sonali M. ;

Waller, Edmund K. ;

Wirk, Baldeep M. ;

Laport, Ginna G. ;

Maloney, David G. ;

Montoto, Silvia ;

Hari, Parameswaran N. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) :273-+

← 1 2 3 4 →